Table 1.
Patient characteristics.
| Factors | Total | Pre-planning 145 Gy |
Intraoperative planning 160 Gy |
|---|---|---|---|
| Patients, n | 408 | 187 (43.3%) | 221 (56.7%) |
| Mean age, years | 66 | 67 | 65 |
| <55 | 25 (6.1%) | 6 (3.2%) | 19 (8.6%) |
| 55–65 | 161 (39.5%) | 69 (36.9%) | 92 (41.6%) |
| >65 | 222 (54.4%) | 112 (59.9%) | 110 (49.8%) |
| T stage | |||
| T1c | 237 (58.2%) | 122 (65.6%) | 115 (52%) |
| T2a | 170 (41.8%) | 64 (34.4%) | 106 (48%) |
| Median PSA (1st–3rd quartiles) |
6.4 (5.4–7.7) | 6.21 (5.2–7.5) | 6.51 (5.6–7.81) |
| Gleason score | |||
| ≤4 | 79 (19.4%) | 50 (26.7%) | 29 (13.1%) |
| 5 | 82 (20.1) | 40 (21.4%) | 42 (19%) |
| 6 | 247 (60.5) | 97 (51.9%) | 150 (67.9%) |
| Prior TUR | 23 (5.7%) | 15 (8.2%) | 8 (3.5%) |
| Median pre-treatment IPSS | 3 | 3 | 3 |
| Median prostate volume (1 st–3rd quartiles) |
37 (30–46) | 37 (30–46.5) | 37 (30–46) |
| Median number of seeds (1 st–3rd quartiles) |
64 (54–67) | 73 (60–88.5) | 59 (50.25–69) |
| Follow up Median (months) (1 st–3rd quartiles) |
64 (38–94) | 93 (69–111) | 46 (30–46) |
PSA = prostate-specific antigen; TUR = transurethral resection; IPSS = International Prostate Symptom Score.